Back
Speaker illustration

Doctor Andrew Ambrosy

Kaiser Permanente, San Francisco Medical Centre and Medical Offices, San Francisco (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association of the ESC

Presentations

Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials

Event: ESC Congress 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Approaches to declining ejection fraction

Access
Like
Thumbnail

Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use

Event: ESC Congress 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Approaches to declining ejection fraction

Access
Like
Thumbnail

Predictive models for worsening heart failure events and death in adults with mild-to-moderate chronic kidney disease

Event: Heart Failure 2025

Topic: Comorbidities

Session: Heart failure, chronic kidney disease, and beyond: understanding risk, prognosis, and outcomes

Access
Like
Thumbnail

New IV iron trials

Event: Heart Failure 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: IV iron – What is the current status and what are the future perspectives

Access
Like
Thumbnail

Recent evidence on ferric derisomaltose in heart failure.

Event: Heart Failure 2021

Topic: Treatment

Session: Iron deficiency and heart failure - evidence is piling up - what's next?

Access
Like
Thumbnail

Angiotensin receptor-neprilysin inhibition in patients with de novo acute decompensated heart failure: a prespecified subgroup analysis of the PIONEER-HF trial

Event: ESC Congress 2019

Topic: Treatment

Session: Treatment of conundrum in acute heart failure

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources